FDA 483 - Corixa Corporation - March 12, 2026

An FDA inspection of Corixa Corporation in Marietta, PA, a drug manufacturer, revealed a deficiency in the system for monitoring environmental conditions in aseptic processing areas. Specifically, the firm failed to properly qualify plates used for environmental monitoring samples at a required incubation temperature. This indicates a lapse in quality control for critical manufacturing processes.